William Blair Reduces Earnings Estimates for Legend Biotech

Legend Biotech Co. (NASDAQ:LEGN) – William Blair reduced their Q1 2025 earnings per share estimates for Legend Biotech in a research note issued on Wednesday, March 12th. William Blair analyst S. Corwin now expects that the company will post earnings of ($0.40) per share for the quarter, down from their prior forecast of ($0.19). The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. William Blair also issued estimates for Legend Biotech’s Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.85) EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.16 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.33 EPS and FY2026 earnings at $0.79 EPS.

A number of other research firms also recently commented on LEGN. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $83.00 target price on shares of Legend Biotech in a report on Monday, December 9th. Royal Bank of Canada reissued an “outperform” rating and issued a $86.00 price target on shares of Legend Biotech in a report on Monday, December 9th. HC Wainwright boosted their price target on Legend Biotech from $73.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, March 12th. Guggenheim reissued a “neutral” rating on shares of Legend Biotech in a report on Wednesday, March 12th. Finally, Piper Sandler reissued an “overweight” rating and issued a $78.00 price target on shares of Legend Biotech in a report on Monday, December 30th. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $79.09.

Legend Biotech Trading Down 2.2 %

Legend Biotech stock opened at $37.20 on Monday. The company has a quick ratio of 4.90, a current ratio of 4.98 and a debt-to-equity ratio of 0.27. Legend Biotech has a 52 week low of $30.17 and a 52 week high of $65.45. The company has a market capitalization of $6.79 billion, a price-to-earnings ratio of -39.16 and a beta of 0.19. The stock has a 50-day moving average price of $35.68 and a 200 day moving average price of $40.74.

Legend Biotech (NASDAQ:LEGN) last released its earnings results on Tuesday, March 11th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.46. Legend Biotech had a negative return on equity of 29.69% and a negative net margin of 66.92%. The firm had revenue of $186.50 million during the quarter, compared to the consensus estimate of $179.00 million. During the same quarter in the previous year, the company posted ($0.40) earnings per share. The company’s revenue was up 134.6% compared to the same quarter last year.

Institutional Trading of Legend Biotech

Several large investors have recently made changes to their positions in LEGN. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Legend Biotech by 9.0% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 177,227 shares of the company’s stock worth $8,636,000 after purchasing an additional 14,672 shares in the last quarter. Thrivent Financial for Lutherans raised its position in Legend Biotech by 38.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 121,377 shares of the company’s stock valued at $5,915,000 after purchasing an additional 33,585 shares in the last quarter. Swiss National Bank raised its position in Legend Biotech by 3.3% in the 3rd quarter. Swiss National Bank now owns 165,194 shares of the company’s stock valued at $8,050,000 after purchasing an additional 5,200 shares in the last quarter. Avior Wealth Management LLC raised its position in Legend Biotech by 3.0% in the 3rd quarter. Avior Wealth Management LLC now owns 11,097 shares of the company’s stock valued at $541,000 after purchasing an additional 323 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Legend Biotech in the 3rd quarter valued at about $316,000. 70.89% of the stock is currently owned by hedge funds and other institutional investors.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).